FDA expands use of Actemra for earlier-stage arthritis

FDA has expanded the approved indication for tocilizumab (Actemra, Genentech) for the treatment of adults with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response to 1 or more disease-modifying antirheumatic drugs (DMARDs).